Gilead Sciences, Inc. $GILD Stake Raised by Strs Ohio

Strs Ohio grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 534,303 shares of the biopharmaceutical company’s stock after buying an additional 22,123 shares during the period. Strs Ohio’s holdings in Gilead Sciences were worth $59,238,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Impact Partnership Wealth LLC boosted its position in Gilead Sciences by 66.2% during the 2nd quarter. Impact Partnership Wealth LLC now owns 13,138 shares of the biopharmaceutical company’s stock worth $1,457,000 after acquiring an additional 5,232 shares during the period. Amalgamated Bank grew its position in Gilead Sciences by 9.2% in the 2nd quarter. Amalgamated Bank now owns 270,927 shares of the biopharmaceutical company’s stock valued at $30,038,000 after buying an additional 22,916 shares in the last quarter. Atria Investments Inc grew its position in Gilead Sciences by 22.3% in the 2nd quarter. Atria Investments Inc now owns 79,026 shares of the biopharmaceutical company’s stock valued at $8,762,000 after buying an additional 14,392 shares in the last quarter. Savvy Advisors Inc. raised its stake in shares of Gilead Sciences by 57.1% in the 2nd quarter. Savvy Advisors Inc. now owns 4,595 shares of the biopharmaceutical company’s stock worth $509,000 after buying an additional 1,670 shares in the last quarter. Finally, Assetmark Inc. raised its stake in shares of Gilead Sciences by 123.2% in the 2nd quarter. Assetmark Inc. now owns 127,417 shares of the biopharmaceutical company’s stock worth $14,127,000 after buying an additional 70,327 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.5%

NASDAQ:GILD opened at $118.50 on Thursday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a fifty-two week low of $86.08 and a fifty-two week high of $124.61. The stock’s 50-day moving average is $115.51 and its two-hundred day moving average is $111.43. The stock has a market cap of $147.04 billion, a PE ratio of 23.61, a price-to-earnings-growth ratio of 0.81 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the sale, the chief financial officer directly owned 157,055 shares in the company, valued at approximately $18,545,054.40. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total value of $1,193,900.00. Following the sale, the chief executive officer owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. This represents a 1.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 71,500 shares of company stock worth $8,336,040. Corporate insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Rothschild & Co Redburn raised their target price on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Daiwa Capital Markets upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price for the company in a report on Tuesday, August 19th. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Finally, Royal Bank Of Canada boosted their price objective on Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.61.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.